Glioma is one of the most treatment-refractory intracranial tumors, and the aberrant expressed Wnt/β-catenin pathway is closely associated with glioma malignancy.
Meanwhile, targeted next-generation sequencing (NGS) revealed the presence of both a beta-catenin (CTNNB1) missense mutation p.Ser33Phe and a mediator complex subunit 12 (MED12) frameshift mutation p.Tyr1278fs in the recurrent intracranial tumor.